

PROLIGHT INITIATES TRIAL AT LONDON HOSPITAL TRUST SUPPORTED BY AN NIHR I4I PDA GRANT

Prolight Diagnostics today announces the company will initiate a trial at Guy's and St Thomas' NHS Foundation Trust and King's College London to pre-validate assay and prototype performance of the Psyros™ POC system. The trial is supported by the recently awarded NIHR i4i PDA grant. Initial data with patient samples will be generated in Q3 2024 and results are expected in Q4 2024.

Clinical Advisory Board member, Professor Michael Marber, will be principal clinical investigator. The data generated from this trial with patient samples will be used for final optimization of the assay and the Psyros platform, to give high levels of confidence when entering the clinical validation study of the commercial POC system in 2025.

"The prestigious i4i PDA grant enables us to perform the pre validation study at highly respected St Thomas' hospital in London. Hence, we will be even better prepared to secure the optimal outcome of the full clinical performance validation study next year," said Ulf Bladin, CEO of Prolight Diagnostics.

"Stratification of patients at risk of heart attack relies on high-sensitivity troponin testing. Bringing these tests to the point-of-care allows faster decision making and earlier safe discharge of a large proportion of patients suspected of heart attack. We look forward greatly to collaborating on this project," said Michael Marber, Consultant Cardiologist at Guy's and St Thomas' NHS Foundation Trust and adjunct Professor of Cardiology at King's College London.

About the NIHR

The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. This is done by:

- Funding high quality, timely research that benefits the NHS, public health and social care;
- Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
- Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
- Attracting, training and supporting the best researchers to tackle complex health and social care challenges;
- Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
- Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries.

NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government.

For further information, please contact:

Prolight Diagnostics AB (publ)

E-mail: info@prolightdx.com

Telephone: +46 73 582 39 87

Website: www.prolightdx.com/en/

About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

[Prolight initiates trial at London hospital Trust supported by an NIHR i4i PDA grant](#)